Literature DB >> 15795412

Nonalcoholic fatty liver disease.

Leon A Adams1, Paul Angulo, Keith D Lindor.   

Abstract

Nonalcoholic fatty liver disease is emerging as the most common chronic liver condition in the Western world. It is associated with insulin resistance and frequently occurs with features of the metabolic syndrome. Disease presentation ranges from asymptomatic elevated liver enzyme levels to cirrhosis with complications of liver failure and hepatocellular carcinoma. Current treatment recommendations are limited to weight loss and exercise, although several promising medications are on the horizon. In this article we discuss the etiology, pathogenesis and diagnosis of nonalcoholic fatty liver disease as well as approaches to its management.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15795412      PMCID: PMC554876          DOI: 10.1503/cmaj.045232

Source DB:  PubMed          Journal:  CMAJ        ISSN: 0820-3946            Impact factor:   8.262


  98 in total

Review 1.  Nonalcoholic fatty liver disease.

Authors:  Paul Angulo
Journal:  N Engl J Med       Date:  2002-04-18       Impact factor: 91.245

2.  Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial.

Authors:  Keith D Lindor; Kris V Kowdley; E Jenny Heathcote; M Edwyn Harrison; Roberta Jorgensen; Paul Angulo; James F Lymp; Lawrence Burgart; Patrick Colin
Journal:  Hepatology       Date:  2004-03       Impact factor: 17.425

3.  Long term prognosis of fatty liver: risk of chronic liver disease and death.

Authors:  S Dam-Larsen; M Franzmann; I B Andersen; P Christoffersen; L B Jensen; T I A Sørensen; U Becker; F Bendtsen
Journal:  Gut       Date:  2004-05       Impact factor: 23.059

4.  Leptin is essential for the hepatic fibrogenic response to chronic liver injury.

Authors:  Isabelle A Leclercq; Geoffrey C Farrell; Rixt Schriemer; Graham R Robertson
Journal:  J Hepatol       Date:  2002-08       Impact factor: 25.083

5.  Polymorphisms of microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in non-alcoholic steatohepatitis.

Authors:  Chikako Namikawa; Zhang Shu-Ping; John Raynor Vyselaar; Yasuko Nozaki; Yoshihisa Nemoto; Masafumi Ono; Naoaki Akisawa; Toshiji Saibara; Makoto Hiroi; Hideaki Enzan; Saburo Onishi
Journal:  J Hepatol       Date:  2004-05       Impact factor: 25.083

6.  A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis.

Authors:  Kittichai Promrat; Glen Lutchman; Gabriel I Uwaifo; Renee J Freedman; Alejandro Soza; Theo Heller; Edward Doo; Marc Ghany; Ahalya Premkumar; Yoon Park; T Jake Liang; Jack A Yanovski; David E Kleiner; Jay H Hoofnagle
Journal:  Hepatology       Date:  2004-01       Impact factor: 17.425

7.  Nonalcoholic fatty liver disease in patients with type 2 diabetes.

Authors:  Zobair M Younossi; Terry Gramlich; Christi A Matteoni; Navdeep Boparai; Arthur J McCullough
Journal:  Clin Gastroenterol Hepatol       Date:  2004-03       Impact factor: 11.382

8.  Leptin is required for fibrogenic responses induced by thioacetamide in the murine liver.

Authors:  Hajime Honda; Kenichi Ikejima; Miyoko Hirose; Mutsuko Yoshikawa; Tie Lang; Nobuyuki Enomoto; Tsuneo Kitamura; Yoshiyuki Takei; Nobuhiro Sato
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

9.  HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity.

Authors:  Shivakumar Chitturi; Martin Weltman; Geoffrey C Farrell; David McDonald; James Kench; Christopher Liddle; Dev Samarasinghe; Rita Lin; Shehan Abeygunasekera; Jacob George
Journal:  Hepatology       Date:  2002-07       Impact factor: 17.425

10.  Metformin in the treatment of patients with non-alcoholic steatohepatitis.

Authors:  A Uygun; A Kadayifci; A T Isik; T Ozgurtas; S Deveci; A Tuzun; Z Yesilova; M Gulsen; K Dagalp
Journal:  Aliment Pharmacol Ther       Date:  2004-03-01       Impact factor: 8.171

View more
  146 in total

1.  A Computer-Aided Diagnosis Scheme For Detection Of Fatty Liver In Vivo Based On Ultrasound Kurtosis Imaging.

Authors:  Hsiang-Yang Ma; Zhuhuang Zhou; Shuicai Wu; Yung-Liang Wan; Po-Hsiang Tsui
Journal:  J Med Syst       Date:  2015-11-12       Impact factor: 4.460

2.  Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF15 signal.

Authors:  Johannes Schmitt; Bo Kong; Grace L Guo; Andreas Geier; Bruno Stieger; Oliver Tschopp; Simon M Schultze; Monika Rau; Achim Weber; Beat Müllhaupt
Journal:  Liver Int       Date:  2014-02-07       Impact factor: 5.828

3.  High fat diet induces ceramide and sphingomyelin formation in rat's liver nuclei.

Authors:  Grzegorz Chocian; Adrian Chabowski; Małgorzata Zendzian-Piotrowska; Ewa Harasim; Bartłomiej Łukaszuk; Jan Górski
Journal:  Mol Cell Biochem       Date:  2010-02-20       Impact factor: 3.396

4.  Treatment options for nonalcoholic Fatty liver disease.

Authors:  Shivakumar Chitturi
Journal:  Therap Adv Gastroenterol       Date:  2008-11       Impact factor: 4.409

5.  Nonalcoholic fatty liver disease.

Authors:  Diana Mager; Eve Roberts
Journal:  CMAJ       Date:  2005-09-27       Impact factor: 8.262

6.  Nonalcoholic fatty liver disease.

Authors:  Pankaj Madan
Journal:  CMAJ       Date:  2005-09-27       Impact factor: 8.262

7.  Hepatic glucose uptake is increased in association with elevated serum γ-glutamyl transpeptidase and triglyceride.

Authors:  Sun-pyo Hong; Tae Soo Noh; Seung-Hwan Moon; Young Seok Cho; Eun Jeong Lee; Joon Young Choi; Byung-Tae Kim; Kyung-Han Lee
Journal:  Dig Dis Sci       Date:  2013-12-11       Impact factor: 3.199

Review 8.  Clinical approaches to non-alcoholic fatty liver disease.

Authors:  Katherine J P Schwenger; Johane P Allard
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

9.  Comparison of fatty liver index with noninvasive methods for steatosis detection and quantification.

Authors:  Shira Zelber-Sagi; Muriel Webb; Nimer Assy; Laurie Blendis; Hanny Yeshua; Moshe Leshno; Vlad Ratziu; Zamir Halpern; Ran Oren; Erwin Santo
Journal:  World J Gastroenterol       Date:  2013-01-07       Impact factor: 5.742

10.  Non-invasive means of measuring hepatic fat content.

Authors:  Sanjeev-R Mehta; E-Louise Thomas; Jimmy-D Bell; Desmond-G Johnston; Simon-D Taylor-Robinson
Journal:  World J Gastroenterol       Date:  2008-06-14       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.